Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022
News
Servier Wins Reuters’ 2022 Patient Champion Award
New Data at ASH 2022 Bolster Servier’s Leadership in Hematology Research
Servier Affirms Commitment to Cancer by Announcing the Opening of a Global R&D Center and Expanded Offices in Boston’s Seaport
Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine
Servier Joins Everest Climb to Fight Cancer Benefitting Fred Hutchinson Cancer Research Center
Servier Submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO® (ivosidenib tablets) for Patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma